Concino Biotech (06185) rose 9.5 percent against the market in early tradingpokerpro.37%, currently quoted at HK$23.35, with a turnover of HK$56.5263 million.
It is reported that in terms of pipeline development, the marketing application for Concino Biotech's 13-valent pneumonia conjugate vaccine PCV13i has been accepted.pokerpro; The infant component DPT DTcP has completed Phase III enrollment of subjects; the adsorbed tetanus vaccine has started Phase III clinical trials; the recombinant herpes zoster vaccine (adenovirus vector) has started Phase I clinical trials in Canada; and the recombinant polio vaccine has started Phase I clinical trials in Australia. In addition, the company and AstraZeneca reached a cooperative development agreement on the research and development of mRNA vaccines.